Symptomatic Nonerosive Gastroesophageal Reflux Disease: Developing Drugs for Treatment
Similar Posts
FDA Roundup: July 14, 2023
The U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency.MediNatura New Mexico, Inc. Expands Voluntary Nationwide Recall of ReBoost Nasal Spray and to include ClearLife Allergy Nasal Spray Due to Microbial Contamination
FOR IMMEDIATE RELEASE – December 16, 2025 – Albuquerque, New Mexico, MediNatura New Mexico, Inc. is voluntarily recalling all lots of ReBoost Nasal Spray to the consumer level. The product has been found to contain yeast/mold and microbial contamination with one species identified as Achromobacter,FDA 483, dated June 11, 2008, (9 pages)
FDA 483, dated June 11, 2008, (9 pages)Biomarker Qualification Program
The Drug Development Tools (DDT) Research Grant Cycle for Fiscal Years (FY) 2024 is now open.MedisourceRx – 717970 – 12/12/2025
Compounding Pharmacy/Adulterated Drug ProductsSun Pharmaceuticals Medicare Ltd. 9/19/2025
Record Date: 9/19/2025
Entity Name: Sun Pharmaceuticals Medicare Ltd.
FEI Number: 3002957541
Record Type: 483
Country: India
Establishment Type: Sterile Drug Manufacturer